Lumida
/ZBIO
⌘K
Zenas Biopharma Inc

Zenas Biopharma Inc

ZBIO
$31.12USD+0.06%+0.02 today

MARKET CAP

2.0B

P/E (TTM)

FWD P/E

DAY RANGE

$31 – $32

52W RANGE

$14
$45

AI Summary

Stalk
Buy NowMedium

ZBIO remains in a Stage 2 uptrend with a rising 200-day SMA and active Lockout Rally dynamics driven by short-covering demand. The medium-term bias is bullish, and the recent pullback into the confluence of the 9EMA, 20EMA, and 50SMA near the support zone around $31–$31.50 was met with buying interest, indicating acceptance. Under the Lockout Rally override, short-term timing is bullish, and a Buy Now at this support confluence is recommended. A decisive break below the 50SMA and EMAs would invalidate this bullish posture.

  • FDA accepted obexelimab BLA for IgG4-RD; PDUFA target May 27, 2027
  • $673.9M cash and equivalents fund operations through Q2 2029
  • Q2 2026 net loss widened to $111.5M from $52.2M a year ago
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2024FY 2025TREND
Sales, Adj.$5.0M$10.0M
YoY %+100.0%
P / Sales21.6x162.4x
EV / Sales-30.8x165.5x
Gross Profit, Adj.$5.0M$10.0M
YoY %+100.0%
Margin %100.0%100.0%
EV / Gross Profit-30.8x165.5x
EBITDA, Adj.$-163.8M$-383.0M
YoY %-133.9%
Margin %-3275.0%-3830.0%
EV / EBITDA0.9x-4.3x
EBIT$-163.9M$-383.1M
YoY %-133.7%
Margin %-3277.8%-3830.6%
EV / EBIT0.9x-4.3x
Net Income$-157.0M$-377.7M
YoY %-140.6%
Net Margin-3139.8%-3777.4%
EPS (GAAP)-$11.89-$8.44
YoY %+29.0%